Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Series D Preferred Stock [Member] Common Stock [Member] At-the-Market Offering [Member]	Series D Preferred Stock [Member] Common Stock [Member] Settlement of Preferred Stock [Member]	Series D Preferred Stock [Member] Common Stock [Member] Cashless Exercise of Warrants [Member]	Series D Preferred Stock [Member] Common Stock [Member] Exercise of Options [Member]	Series D Preferred Stock [Member] Common Stock [Member] Exercise of Warrants [Member]	Series D Preferred Stock [Member] Common Stock [Member]	Series E Preferred Stock [Member] Additional Paid-in Capital [Member] At-the-Market Offering [Member]	Series E Preferred Stock [Member] Additional Paid-in Capital [Member] Settlement of Preferred Stock [Member]	Series E Preferred Stock [Member] Additional Paid-in Capital [Member] Exercise of Options [Member]	Series E Preferred Stock [Member] Additional Paid-in Capital [Member] Exercise of Warrants [Member]	Series E Preferred Stock [Member] Additional Paid-in Capital [Member] Trek Therapeutics, PBC [Member]	Series E Preferred Stock [Member] Additional Paid-in Capital [Member]	Series E Preferred Stock [Member] Retained Earnings [Member]	Series C Preferred Stock [Member] Settlement of Preferred Stock [Member]	Series C Preferred Stock [Member]	Noncontrolling Interest [Member] Trek Therapeutics, PBC [Member]	Noncontrolling Interest [Member]	At-the-Market Offering [Member]	Exercise of Options [Member]	Exercise of Warrants [Member]	Trek Therapeutics, PBC [Member]	Total
Balance at Dec. 31, 2019						$ 23						$ 115,910	$ (104,787)				$ 515					$ 11,661
Balance (in Shares) at Dec. 31, 2019						23,323,087
Sale of common stock						$ 5	$ 2,228					25,210						$ 2,228				25,215
Sale of common stock (in Shares)	424,357					4,687,500
Sale of subsidiary shares to non-controlling interest												7,124					3,468					$ 10,592
Sale of subsidiary shares to non-controlling interest (in Shares)																						83,055
Common stock issued for services						$ 1						4,399										$ 4,400
Common stock issued for services (in Shares)						679,555
Fair value of subsidiary shares issued to acquire research and development											$ 2,439	1,051				$ 735	248				$ 3,174	1,299
Stock based compensation												17,983					2,782					20,765
Stock based compensation (in Shares)						219,334
Preferred Stock dividend												(14)										(14)
Net loss													(52,218)				(6,922)					$ (59,140)
Common stock issued upon conversion of preferred stock and accrued dividends								$ 70				110		$ 70	$ 110
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)		15,516				29,334
Common stock issued upon exercise of warrants					$ 1					$ 2,089										$ 2,090
Common stock issued upon exercise of warrants (in Shares)			12,840		542,646
Common stock issued in exchange for subsidiary shares												24					(24)
Common stock issued in exchange for subsidiary shares (in Shares)						83,055									44,850
Common stock issued upon exercise of options				$ 1					$ 2,721										$ 2,722
Common stock issued upon exercise of options (in Shares)				586,825		160,743																1,203,223
Balance at Dec. 31, 2020						$ 31						181,344	(157,005)				802					$ 25,172
Balance (in Shares) at Dec. 31, 2020						30,764,792																30,764,792
Sale of common stock							$ 1,300											$ 1,300
Sale of common stock (in Shares)	251,720
Change in fair value of modified options												313					8					$ 321
Sale of subsidiary shares to non-controlling interest						$ 3						9,001										9,004
Sale of subsidiary shares to non-controlling interest (in Shares)						2,500,000
Common stock issued for services						$ 1						3,974										3,975
Common stock issued for services (in Shares)						1,124,341
Stock based compensation						$ 1						5,176					348					5,525
Stock based compensation (in Shares)						916,952
Preferred Stock dividend												(9)										(9)
Net loss													(31,917)				(939)					$ (32,856)
Common stock issued upon conversion of preferred stock and accrued dividends								$ 28						$ 28
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)		9,375
Common stock issued upon exercise of options (in Shares)																			9,375			9,375
Balance at Dec. 31, 2021						$ 36						$ 201,127	$ (188,922)				$ 219					$ 12,460
Balance (in Shares) at Dec. 31, 2021						35,567,180																35,567,180